Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso

Inclusion Criteria: Each subject receiving study vaccine (Vi-TCV or IPV) must satisfy the following inclusion criteria at study entry: * Male or female child 9 through11 months of age for cohort 1, or 15 months through 23 months of age for cohort 2, and in good health at the time of study vaccination. * A child whose parent or guardian resides primarily within the study area at the time of study vaccinations and who intends to be present in the area for the duration of the trial. * A child whose parent or guardian has voluntarily given informed consent. Exclusion Criteria: No subject receiving study vaccine (Vi-TCV or IPV) may have any of the following exclusion criteria at study entry: * History of documented hypersensitivity to any component of the vaccine. * Prior receipt of any typhoid vaccine. * History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis. * Known history of diabetes, tuberculosis, cancer, chronic kidney, heart, or liver disease, progressive neurological disorders, poorly controlled seizures, or terminal illness. * Severe malnutrition as determined by a MUAC \< 12.5 cm. * Receipt of any other investigational intervention in the last 6 months or anticipated during the course of the study. * Receipt of blood products in the last 6 months. * Known HIV infection or exposure or other immunosuppressive conditions. * Receipt of systemic immunosuppressant or systemic corticosteroids. * Receipt of any measles-rubella-containing va…